Gumintad, Lea Mae P.
HRN: 24-99-46 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/19/2024
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
05/19/2024
05/26/2024
IV
600mg
Q6
Hirschsprung Disease; Post-op
Waiting Final Action
Indication: Empiric Type of Infection: Intra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes